麻醉疼痛科指南

订阅

MedSci主页 / 所有栏目 / 麻醉疼痛科指南

2021 欧洲临床实践建议：阿片类药物治疗慢性非癌性疼痛—第2部分

2021-03-02 欧洲疼痛联盟 Eur J Pain . 2021 Mar 2.

阿片类药物

2021年3月，欧洲疼痛联盟(EFIC)发布了阿片类药物治疗慢性非癌性疼痛临床实践建议，本文为该实践建议的第2部分，主要内容涉及特殊情况下的应用。

中文标题：

2021 欧洲临床实践建议：阿片类药物治疗慢性非癌性疼痛—第2部分

英文标题：

European clinical practice recommendations on opioids for chronic noncancer pain - Part 2: Special situations

发布机构：

欧洲疼痛联盟

发布日期：

2021-03-02

简要介绍：

2021年3月，欧洲疼痛联盟(EFIC)发布了阿片类药物治疗慢性非癌性疼痛临床实践建议，本文为该实践建议的第2部分，主要内容涉及特殊情况下的应用。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=阿片类药物治疗慢性非癌性疼痛—第2部分.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9405c1c0020e00a2, title=2021 欧洲临床实践建议：阿片类药物治疗慢性非癌性疼痛—第2部分, enTitle=European clinical practice recommendations on opioids for chronic noncancer pain - Part 2: Special situations, guiderFrom=Eur J Pain . 2021 Mar 2., authorId=0, author=, summary=2021年3月，欧洲疼痛联盟(EFIC)发布了阿片类药物治疗慢性非癌性疼痛临床实践建议，本文为该实践建议的第2部分，主要内容涉及特殊情况下的应用。, cover=https://img.medsci.cn/2021313/1615648872738_2020535.jpg, journalId=0, articlesId=null, associationId=1730, associationName=欧洲疼痛联盟, associationIntro=, copyright=0, guiderPublishedTime=Tue Mar 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p><span style="color: #373737;">2021年3月，欧洲疼痛联盟(EFIC)发布了阿片类药物治疗慢性非癌性疼痛临床实践建议，本文为该实践建议的第2部分，主要内容涉及特殊情况下的应用。</span></p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=9680, tagName=阿片类药物)], categoryList=[CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=9680, guiderKeyword=阿片类药物, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4556, appHits=52, showAppHits=0, pcHits=384, showPcHits=4504, likes=0, shares=5, comments=9, approvalStatus=1, publishedTime=Sat Mar 13 23:54:01 CST 2021, publishedTimeString=2021-03-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Mar 13 23:21:17 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Thu Jan 04 02:59:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=阿片类药物治疗慢性非癌性疼痛—第2部分.pdf)])
阿片类药物治疗慢性非癌性疼痛—第2部分.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1003436, encodeId=93031003436e6, content=学习一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:11:17 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003432, encodeId=93f8100343232, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:06:30 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974500, encodeId=0d019e45006c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 17 22:06:52 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948377, encodeId=3dc29483e78c, content=根据指南共识指导，减少不良反应发生率，增加镇痛效果。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/d811c9580eab4bcea45ec70e3e5530ab/73aae907cf224c87b63853ee55aa3640.jpg, createdBy=28dd5450307, createdName=卡特米, createdTime=Mon Mar 15 15:39:57 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948232, encodeId=6284948232b9, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Mon Mar 15 06:22:03 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-07-28 146ebbd3m07暂无昵称

    学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1003436, encodeId=93031003436e6, content=学习一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:11:17 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003432, encodeId=93f8100343232, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:06:30 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974500, encodeId=0d019e45006c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 17 22:06:52 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948377, encodeId=3dc29483e78c, content=根据指南共识指导，减少不良反应发生率，增加镇痛效果。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/d811c9580eab4bcea45ec70e3e5530ab/73aae907cf224c87b63853ee55aa3640.jpg, createdBy=28dd5450307, createdName=卡特米, createdTime=Mon Mar 15 15:39:57 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948232, encodeId=6284948232b9, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Mon Mar 15 06:22:03 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-07-28 146ebbd3m07暂无昵称

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1003436, encodeId=93031003436e6, content=学习一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:11:17 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003432, encodeId=93f8100343232, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:06:30 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974500, encodeId=0d019e45006c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 17 22:06:52 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948377, encodeId=3dc29483e78c, content=根据指南共识指导，减少不良反应发生率，增加镇痛效果。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/d811c9580eab4bcea45ec70e3e5530ab/73aae907cf224c87b63853ee55aa3640.jpg, createdBy=28dd5450307, createdName=卡特米, createdTime=Mon Mar 15 15:39:57 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948232, encodeId=6284948232b9, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Mon Mar 15 06:22:03 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-06-17 麻无赦

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1003436, encodeId=93031003436e6, content=学习一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:11:17 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003432, encodeId=93f8100343232, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:06:30 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974500, encodeId=0d019e45006c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 17 22:06:52 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948377, encodeId=3dc29483e78c, content=根据指南共识指导，减少不良反应发生率，增加镇痛效果。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/d811c9580eab4bcea45ec70e3e5530ab/73aae907cf224c87b63853ee55aa3640.jpg, createdBy=28dd5450307, createdName=卡特米, createdTime=Mon Mar 15 15:39:57 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948232, encodeId=6284948232b9, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Mon Mar 15 06:22:03 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-03-15 卡特米

    根据指南共识指导，减少不良反应发生率，增加镇痛效果。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1003436, encodeId=93031003436e6, content=学习一下 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:11:17 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003432, encodeId=93f8100343232, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef975177145, createdName=146ebbd3m07暂无昵称, createdTime=Wed Jul 28 21:06:30 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974500, encodeId=0d019e45006c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 17 22:06:52 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948377, encodeId=3dc29483e78c, content=根据指南共识指导，减少不良反应发生率，增加镇痛效果。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/d811c9580eab4bcea45ec70e3e5530ab/73aae907cf224c87b63853ee55aa3640.jpg, createdBy=28dd5450307, createdName=卡特米, createdTime=Mon Mar 15 15:39:57 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948232, encodeId=6284948232b9, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b35447270, createdName=ms4000000206232216, createdTime=Mon Mar 15 06:22:03 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-03-15 ms4000000206232216

    非常好

    0

相关指南

2021 欧洲临床实践建议：阿片类药物治疗慢性非癌性疼痛—第1部分

欧洲疼痛联盟(EFIC,European Pain Federation) · 2021-03-02

2021 CPIC指南：CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗

临床药物基因组学实施联盟(CPIC,Clinical Pharmacogenetics Implementation Consortium) · 2021-01-02

2020 CAEP立场声明：阿片类药物使用障碍患者的急诊管理

加拿大急诊医师协会(CAEP,Canadian Association of Emergency Physicians) · 2020-11-20

关于预防成年手术患者阿片类药物相关伤害的国际多学科共识声明 2020

暂未更新 · 2020-10-06

2020 ASAM国家实践指南：阿片类药物使用障碍的治疗

暂未更新 · 2020-04-20

2020 CCSHM指南：阿片类使用障碍

加拿大老年人心理健康联盟(CCSHM,Canadian Coalition for Seniors’ Mental Health) · 2020-03-30

拓展阅读

2014 新西兰实践指南：阿片类药物替代治疗

新西兰卫生部(New Zealand Ministry of Health) · 2014-04-11

2014 WHO阿片类药物应用过量的社区管理

世界卫生组织(WHO,The World Health Organization) · 2014-10-01

JAMA：CDC 2016 阿片类药物镇痛使用指南

美国疾病控制与预防中心(CDC,Centers for Disease Control and Prevention) · 2016-03-21

2016 香港指南：阿片类药物治疗慢性非癌痛

香港医学相关专家组（统称） · 2016-10-05

【精华指南】驾驭癌性疼痛，权衡阿片药物剂量，医生无需纠结

暂未更新 · 2017-03-09

2016 CPSBC阿片类药物滥用指南：美沙酮和丁丙诺啡

不列颠哥伦比亚内外科医师学会(CPSBC,College of Physicians and Surgeons of British Columbia) · 2016-07-01